Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO)
Authors:
- 8 July 2014
- journal article
- review article
- Published by Wiley in Neurourology and Urodynamics
- Vol. 33 (S3) , S21-S25
Abstract
This chapter focuses on the position of botulinum toxin type A in the treatment pathway for overactive bladder (OAB) and neurogenic lower urinary tract dysfunction associated with neurogenic detrusor overactivity (NDO), and the recommendations of the major international guideline groups. Recommendations of different guideline groups may vary, especially when evidence is weak, often because of differences in methodology and panel composition.Relevant guidelines from the European Association of Urology, American Urological Association, and the UK National Institute for Care and Clinical Excellence were reviewed, and the recommendations that form the basis of the treatment algorithms have been discussed. Any differences between guidelines have been highlighted and special emphasis made on the position of botulinum toxin type A in these pathways.In all the reviewed guidelines, botulinum toxin type A is recommended, alongside sacral nerve neuromodulation, to treat OAB and NDO in patients who have failed oral therapy. The evidence base is consistent, but further evidence is required regarding optimal dosing regimens and injection technique. Neurourol. Urodynam. 33:S21–S25, 2014.Keywords
This publication has 13 references indexed in Scilit:
- OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled TrialJournal of Urology, 2013
- 1367 ONABOTULINUMTOXINA IN PATIENTS WITH OVERACTIVE BLADDER AND URINARY INCONTINENCE: CONSISTENT EFFECT OVER REPEAT TREATMENTJournal of Urology, 2013
- Urodynamic Studies in Adults: AUA/SUFU GuidelineJournal of Urology, 2012
- Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU GuidelineJournal of Urology, 2012
- Anticholinergic Therapy vs. OnabotulinumtoxinA for Urgency Urinary IncontinenceNew England Journal of Medicine, 2012
- Phase 3 Efficacy and Tolerability Study of OnabotulinumtoxinA for Urinary Incontinence From Neurogenic Detrusor OveractivityJournal of Urology, 2012
- Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled TrialEuropean Urology, 2011
- Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging TrialJournal of Urology, 2010
- Results of Sacral Neuromodulation Therapy for Urinary Voiding Dysfunction: Outcomes of a Prospective, Worldwide Clinical StudyJournal of Urology, 2007
- Does Eradicating Bacteriuria Affect the Severity of Chronic Urinary Incontinence in Nursing Home Residents?Annals of Internal Medicine, 1995